Accordingly, a series of multicenter clinical trials have been conducted in HF patients using compounds that trap TNFα, comprising infliximab, an antibody directed to TNFα, and etanercept, a soluble recombinant receptor of TNFα. This evidence concerns the gene TNF and hydrops fetalis.